
- /
- Supported exchanges
- / US
- / PLRX.NASDAQ
Pliant Therapeutics Inc (PLRX NASDAQ) stock market data APIs
Pliant Therapeutics Inc Financial Data Overview
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Pliant Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Pliant Therapeutics Inc data using free add-ons & libraries
Get Pliant Therapeutics Inc Fundamental Data
Pliant Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -217 976 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.6595
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pliant Therapeutics Inc News

3 Promising Penny Stocks With Market Caps Under $500M
As the U.S. stock market faces volatility with regional bank shares plummeting and bond yields hitting lows, investors are increasingly on the lookout for alternative opportunities. Penny stocks, thou...


Align downgraded, NetEase upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

Biotech Stocks Rally After-Hours On Trial Updates, Insider Buys, And Conference Buzz
(RTTNews) - Biotech stocks lit up the after-hours session on September 9, 2025, with several small- and mid-cap names posting sharp gains following fresh clinical updates, insider buying, and investor...

Pliant Therapeutics stock price target slashed by Piper Sandler
Investing.com - Piper Sandler has lowered its price target on Pliant Therapeutics (NASDAQ:PLRX) to $4.00 from $17.00 while maintaining an Overweight rating on the stock. The stock has fallen over 86% ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.